China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a partnership with compatriot firm Zein Biotechnology to collaborate on the commercialization of its PCSK9 monoclonal antibody (mAb), ongericimab (JS002), in mainland China. The financial details of the agreement have not been disclosed.
Regulatory Filings and Phase III Study Progress
Two market filings for ongericimab have been submitted to the National Medical Products Administration (NMPA) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia in April of this year. Additionally, the drug has completed enrollment for a Phase III study in heterozygous familial hypercholesterolemia, indicating significant progress in the drug’s development and potential market entry.-Fineline Info & Tech
